Regulation of D2 dopamine receptors by amiloride and amiloride analogs

SR Hoare and PG Strange

Research School of Biosciences, Biological Laboratory, The University, Canterbury, UK.

Allosteric regulation of rat D2 dopamine receptors by amiloride and amiloride analogs has been studied by investigating their ability to accelerate the dissociation of [3H]spiperone from the receptors expressed in Ltk- cells. The amiloride analogs were more potent and produced a greater maximal effect on the rate of [3H]spiperone dissociation than did amiloride. [3H]Spiperone dissociation was biphasic and could be resolved into contributions from fast and slow rates in the absence and presence of the modulators. Methylisobutylamiloride accelerated both the fast and slow rates of dissociation and modulated the proportions of the two rates. The association of [3H]spiperone in the absence of modulators was also biphasic. The combination of the two sets of association and dissociation rate constants gave very similar equilibrium dissociation constants, and this was confirmed in equilibrium binding experiments that were consistent with a single binding site. It is proposed that there are two binding states for [3H]spiperone that can be distinguished kinetically but not in equilibrium binding experiments. The proportions of these states are differentially modulated with the use of sodium ions and magnesium ions, whereas GTP has no significant effect. Allosteric regulation of [3H]spiperone binding by methylisobutylamiloride could also be observed in saturation and inhibition binding experiments. These effects can be accounted for in a model in which the modulator binds to the competitive site of the receptor and to an allosteric site on the receptor from which it exerts negatively cooperative effects on [3H]spiperone binding to the competitive site and positively cooperative effects on the binding of the modulator to the competitive site.

Volume 50, Issue 5, pp. 1295-1308, 11/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				L. H. Heitman, K. Ye, J. Oosterom, and A. P. IJzerman Amiloride Derivatives and a Nonpeptidic Antagonist Bind at Two Distinct Allosteric Sites in the Human Gonadotropin-Releasing Hormone Receptor Mol. Pharmacol., June 1, 2008; 73(6): 1808 - 1815. [Abstract] [Full Text] [PDF]

				A. Christopoulos and T. Kenakin G Protein-Coupled Receptor Allosterism and Complexing Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374. [Abstract] [Full Text] [PDF]

				J. A. Schetz and D. R. Sibley The Binding-Site Crevice of the D4 Dopamine Receptor Is Coupled to Three Distinct Sites of Allosteric Modulation J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 359 - 363. [Abstract] [Full Text]

				D. A. Hall Modeling the Functional Effects of Allosteric Modulators at Pharmacological Receptors: An Extension of the Two-State Model of Receptor Activation Mol. Pharmacol., April 13, 2001; 58(6): 1412 - 1423. [Abstract] [Full Text]

				J. Ellis and M. Seidenberg Interactions of Alcuronium, TMB-8, and Other Allosteric Ligands with Muscarinic Acetylcholine Receptors: Studies with Chimeric Receptors Mol. Pharmacol., April 13, 2001; 58(6): 1451 - 1460. [Abstract] [Full Text]

				V. Blandin, P. Vigne, J. P. Breittmayer, and C. Frelin Allosteric Inhibition of Endothelin ETA Receptors by 3,5-Dibromosalicylic Acid Mol. Pharmacol., April 13, 2001; 58(6): 1461 - 1469. [Abstract] [Full Text]

				P. G. Strange Antipsychotic Drugs: Importance of Dopamine Receptors for Mechanisms of Therapeutic Actions and Side Effects Pharmacol. Rev., March 1, 2001; 53(1): 119 - 134. [Abstract] [Full Text] [PDF]

				A. Talbodec, N. Berkane, V. Blandin, J. P. Breittmayer, E. Ferrari, C. Frelin, and P. Vigne Aspirin and Sodium Salicylate Inhibit Endothelin ETA Receptors by an Allosteric Type of Mechanism Mol. Pharmacol., April 1, 2000; 57(4): 797 - 804. [Abstract] [Full Text]

				J. A. Schetz, P. S. Benjamin, and D. R. Sibley Nonconserved Residues in the Second Transmembrane-Spanning Domain of the D4 Dopamine Receptor Are Molecular Determinants of D4-Selective Pharmacology Mol. Pharmacol., January 1, 2000; 57(1): 144 - 152. [Abstract] [Full Text]

				C. Tränkle, O. Weyand, A. Schröter, and K. Mohr Using a Radioalloster to Test Predictions of the Cooperativity Model for Gallamine Binding to the Allosteric Site of Muscarinic Acetylcholine M2 Receptors Mol. Pharmacol., November 1, 1999; 56(5): 962 - 965. [Abstract] [Full Text]

				N. J. M. Birdsall, T. Farries, P. Gharagozloo, S. Kobayashi, S. Lazareno, and M. Sugimoto Subtype-Selective Positive Cooperative Interactions Between Brucine Analogs and Acetylcholine at Muscarinic Receptors: Functional Studies Mol. Pharmacol., April 1, 1999; 55(4): 778 - 786. [Abstract] [Full Text]

				C. Tränkle, E. Mies-Klomfass, M. H. B. Cid, U. Holzgrabe, and K. Mohr Identification of a [3H]Ligand for the Common Allosteric Site of Muscarinic Acetylcholine M2 Receptors Mol. Pharmacol., July 1, 1998; 54(1): 139 - 145. [Abstract] [Full Text]

				R. A. Leppik, S. Lazareno, A. Mynett, and N. J. M. Birdsall Characterization of the Allosteric Interactions between Antagonists and Amiloride Analogues at the Human alpha 2A-Adrenergic Receptor Mol. Pharmacol., May 1, 1998; 53(5): 916 - 925. [Abstract] [Full Text]

				S. Lazareno, P. Gharagozloo, D. Kuonen, A. Popham, and N. J. M. Birdsall Subtype-Selective Positive Cooperative Interactions between Brucine Analogues and Acetylcholine at Muscarinic Receptors: Radioligand Binding Studies Mol. Pharmacol., March 1, 1998; 53(3): 573 - 589. [Abstract] [Full Text]

				D. Armstrong and P. G. Strange Dopamine D2 Receptor Dimer Formation. EVIDENCE FROM LIGAND BINDING J. Biol. Chem., June 15, 2001; 276(25): 22621 - 22629. [Abstract] [Full Text] [PDF]